Crohn's & Colitis Foundation: Comprehensive Company Profile

Background

The Crohn's & Colitis Foundation is a non-profit, volunteer-driven organization dedicated to curing Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), and improving the quality of life for affected individuals. Since its inception in 1967, the Foundation has been instrumental in every major breakthrough in IBD research, investing over $500 million to uncover causes, develop treatments, and pursue cures.

Key Strategic Focus

The Foundation's strategic objectives encompass:

• Research Programs: Funding over 2,500 research projects globally, with a $34.8 million investment in 2023.

• Patient Education and Support: Offering resources such as the IBD Help Center, MyIBDLearning Education Series, peer-to-peer mentoring, and Camp Oasis for children with IBD.

• Professional Education and Engagement: Hosting the annual Crohn’s & Colitis Congress® and providing educational resources to healthcare providers.

• Advocacy: Promoting policies for better access to insurance and medication, and increased research funding.

• Community Events: Organizing fundraising events like Take Steps and Team Challenge to raise awareness and support for IBD research and programs.

Financials and Funding

In 2022, the Foundation reported total income of $88,484,137, with program expenses accounting for 83% of total expenses.

Pipeline Development

The Foundation's research initiatives include:

• IBD Plexus®: A comprehensive database and biosample repository to accelerate research.

• IBD Ventures: Investing in innovative products under development to expedite new treatments, devices, and diagnostic tools.

• IBD Qorus®: A national quality of care initiative involving over 50 GI practices to enhance patient outcomes.

Technological Platform and Innovation

The Foundation's notable technological platforms include:

• IBD Plexus®: A large-scale database and biosample repository facilitating research collaborations.

• IBD Ventures: A venture philanthropy initiative investing in innovative IBD treatments and diagnostics.

• IBD Qorus®: A quality of care initiative promoting best practices among GI providers.

Leadership Team

• Michael Osso: President and CEO since August 2015, leading the Foundation's mission and operations.

• Allison Coffey: Chief Development & Field Officer, overseeing fundraising and community engagement.

• Christy DeSantis: Chief Marketing & Communications Officer, leading brand and communication strategies.

• Sharon Lungrin: Chief Operating Officer, managing strategic and operational functions.

• Alan Moss, MD: Chief Scientific Officer, directing scientific research initiatives.

• Rohit Suri: Chief Technology Officer, overseeing technological advancements.

• Chris Fidyk: Executive Vice President, Business Development, leading business growth strategies.

• Laura D. Wingate: Executive Vice President, Education, Support & Advocacy, managing educational and advocacy programs.

Leadership Changes

Recent leadership appointments include:

• Sharon Lungrin: Appointed as Chief Operating Officer, bringing experience in strategy and operations across various sectors.

• Alan Moss, MD: Joined as Chief Scientific Officer, with a background in gastroenterology and translational research.

• Chris Fidyk: Appointed as Executive Vice President, Business Development, with over 20 years in healthcare and life sciences.

Competitor Profile

Market Insights and Dynamics

The IBD sector is characterized by:

• Prevalence: Approximately 1 in 100 individuals in the U.S. are affected by IBD.

• Research Investment: The Foundation has invested over $500 million in IBD research.

Competitor Analysis

Key organizations in the IBD space include:

• Crohn's and Colitis Canada: Focuses on research and patient support in Canada.

• Crohn's and Colitis UK: Provides resources and advocacy for IBD patients in the UK.

• European Federation of Crohn's and Ulcerative Colitis Associations: A collective of European IBD organizations.

Strategic Collaborations and Partnerships

The Foundation collaborates with:

• American Gastroenterological Association (AGA): Partnered to enhance patient-provider communication in the IBD community.

• Centers for Disease Control and Prevention (CDC): Partnered on the INPUT study to determine IBD incidence and prevalence in the U.S.

• Corporate Partners: Collaborates with companies like AbbVie, Amgen, and Takeda Pharmaceuticals to support research and patient programs.

Operational Insights

The Foundation's strategic considerations include:

• Research Leadership: Funding over 2,500 research projects globally.

• Patient Support: Serving more than 1.2 million patients annually through education and support programs.

• Advocacy Efforts: Engaging in federal campaigns to secure funding and policy changes for IBD research and patient care.

Strategic Opportunities and Future Directions

The Foundation's strategic roadmap includes:

• Advancing New Therapies: Supporting the discovery and development of treatments addressing unmet patient needs.

• Supporting Researchers: Attracting and developing innovative clinicians and researchers to advance IBD research.

• Financial Growth: Aiming to become a $100 million organization by 2025 through expanded reach and engagement.

Contact Information

For more information, visit the Crohn's & Colitis Foundation's official website.